184 related articles for article (PubMed ID: 17049687)
21. Field trial of oral cholera vaccines in Bangladesh.
Clemens JD; Harris JR; Sack DA; Chakraborty J; Ahmed F; Stanton BF; Huda N; Khan MR; Khan MU; Kay BA
Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):417-22. PubMed ID: 3217823
[No Abstract] [Full Text] [Related]
22. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response.
Mahalanabis D; Ramamurthy T; Nair GB; Ghosh A; Shaikh S; Sen B; Thungapathra M; Ghosh RK; Pazhani GP; Nandy RK; Jana S; Bhattacharya SK
Vaccine; 2009 Jul; 27(35):4850-6. PubMed ID: 19523608
[TBL] [Abstract][Full Text] [Related]
23. Oral vaccines for cholera control.
Chaturvedi S; Chaturvedi S
Natl Med J India; 1997; 10(1):17-8. PubMed ID: 9069701
[TBL] [Abstract][Full Text] [Related]
24. Use of oral cholera vaccine as a vaccine probe to determine the burden of culture-negative cholera.
Im J; Islam MT; Ahmmed F; Kim DR; Chon Y; Zaman K; Khan AI; Ali M; Marks F; Qadri F; Clemens JD
PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007179. PubMed ID: 30870416
[TBL] [Abstract][Full Text] [Related]
25. Immune responses to cholera in children.
Leung DT; Chowdhury F; Calderwood SB; Qadri F; Ryan ET
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):435-44. PubMed ID: 22512753
[TBL] [Abstract][Full Text] [Related]
26. Cholera vaccine inactivated oral.
Drugs R D; 1999 Sep; 2(3):193-4. PubMed ID: 10641223
[No Abstract] [Full Text] [Related]
27. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam.
Thiem VD; Deen JL; von Seidlein L; Canh DG; Anh DD; Park JK; Ali M; Danovaro-Holliday MC; Son ND; Hoa NT; Holmgren J; Clemens JD
Vaccine; 2006 May; 24(20):4297-303. PubMed ID: 16580760
[TBL] [Abstract][Full Text] [Related]
28. Prospects for control of cholera with oral vaccines.
Sack RB
J Diarrhoeal Dis Res; 1992 Mar; 10(1):1-3. PubMed ID: 1619235
[No Abstract] [Full Text] [Related]
29. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
30. Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.
Kabir S
Clin Vaccine Immunol; 2014 Sep; 21(9):1195-205. PubMed ID: 25056361
[TBL] [Abstract][Full Text] [Related]
31. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Stewart-Tull DE; Lucas C; Bleakley CR
Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
[TBL] [Abstract][Full Text] [Related]
32. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
[TBL] [Abstract][Full Text] [Related]
33. Home-grown Vietnamese cholera vaccine "completely safe".
Quirk M
Lancet Infect Dis; 2002 Apr; 2(4):198. PubMed ID: 11937407
[No Abstract] [Full Text] [Related]
34. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation.
Ravichandran M; Ali SA; Rashid NH; Kurunathan S; Yean CY; Ting LC; Bakar AS; Lalitha P; Zainuddin ZF
Vaccine; 2006 May; 24(18):3750-61. PubMed ID: 16102875
[TBL] [Abstract][Full Text] [Related]
35. Establishment of an adult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae.
Nygren E; Li BL; Holmgren J; Attridge SR
Infect Immun; 2009 Aug; 77(8):3475-84. PubMed ID: 19470748
[TBL] [Abstract][Full Text] [Related]
36. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.
Año G; Esquisabel A; Pastor M; Talavera A; Cedré B; Fernández S; Sifontes S; Aranguren Y; Falero G; García L; Solís RL; Pedraz JL
Vaccine; 2011 Aug; 29(34):5758-64. PubMed ID: 21683110
[TBL] [Abstract][Full Text] [Related]
37. Relationship between neighbourhood-level killed oral cholera vaccine coverage and protective efficacy: evidence for herd immunity.
Emch M; Ali M; Park JK; Yunus M; Sack DA; Clemens JD
Int J Epidemiol; 2006 Aug; 35(4):1044-50. PubMed ID: 16723370
[TBL] [Abstract][Full Text] [Related]
38. Misleading negative findings in a field trial of killed, oral cholera vaccine in Peru.
Clemens JD; Sack DA; Ivanoff B
J Infect Dis; 2001 Apr; 183(8):1306-9. PubMed ID: 11262221
[No Abstract] [Full Text] [Related]
39. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial.
Sur D; Kanungo S; Sah B; Manna B; Ali M; Paisley AM; Niyogi SK; Park JK; Sarkar B; Puri MK; Kim DR; Deen JL; Holmgren J; Carbis R; Rao R; Nguyen TV; Han SH; Attridge S; Donner A; Ganguly NK; Bhattacharya SK; Nair GB; Clemens JD; Lopez AL
PLoS Negl Trop Dis; 2011 Oct; 5(10):e1289. PubMed ID: 22028938
[TBL] [Abstract][Full Text] [Related]
40. Toxin-coregulated pilus-loaded microparticles as a vaccine against Vibrio cholerae O139.
Du Y; Jia WX; Liu L
Chin Med J (Engl); 2004 Apr; 117(4):618-20. PubMed ID: 15109462
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
